Nutritional and metabolic issues in inflammatory bowel disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 6, Issue 5, 2003, Pages 569-576

  Cabré, Eduard ^a   Gassull, Miguel A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Crohn's disease; Dietary fat; Insulin like growth factor 1; Metabolic bone disease; Prebiotics; Probiotics; Ulcerative colitis

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; C REACTIVE PROTEIN; CALCIUM; CYANOCOBALAMIN; HOMOCYSTEINE; HUMAN GROWTH HORMONE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INULIN; MAGNESIUM; MEDIUM CHAIN TRIACYLGLYCEROL; METALLOPROTEINASE; MONOUNSATURATED FATTY ACID; OLEIC ACID; OLIVE OIL; PECTIN; PLACEBO; POLYUNSATURATED FATTY ACID; PREDNISONE; PROBIOTIC AGENT; PYRIDOXINE; SATURATED FATTY ACID; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STARCH; TRIOLEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D; VSL 3;

ARTICHOKE; BANANA; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; BODY COMPOSITION; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; DIETARY FIBER; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERIC FEEDING; ENTERITIS; GARLIC; GROWTH RETARDATION; HUMAN; HYPERHOMOCYSTEINEMIA; ILEITIS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; LOW FAT DIET; MAGNESIUM BLOOD LEVEL; META ANALYSIS; METABOLIC BONE DISEASE; METABOLIC DISORDER; NUTRITIONAL DISORDER; OXIDATIVE STRESS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOYBEAN; STREPTOCOCCUS SALIVARIUS; SYSTEMATIC REVIEW; THROMBOSIS; ULCERATIVE COLITIS; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; ADULT; BLOOD; CHILD; FAT INTAKE; GROWTH DISORDER; METABOLISM; PATHOPHYSIOLOGY;

ADULT; BONE DISEASES, METABOLIC; CHILD; DIETARY FATS; ENTERAL NUTRITION; GROWTH DISORDERS; HUMANS; INFLAMMATORY BOWEL DISEASES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; NUTRITION DISORDERS; PROBIOTICS;

EID: 1542676032     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200309000-00011     Document Type: Review

References (79)

1. Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with Crohn's disease. Gut 1993; 34:939-943.
2. Motil KJ, Grand RJ, Daviskraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: A prospective study. Gastroenterology 1993; 105:681-691.
3. Markowitz J, Daum F. Growth impairment in pediatric inflammatory bowel disease. Am J Gastroenterol 1994; 89:319-326
4. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999; 28:445-458
5. Ballinger AB, Azooz O, El-Haj T, et al. Growth failure occurs through a decrease in insulin-like growth factor 1 with is independent of undernutrition in a rat model of colitis. Gut 2000; 46:694-700.
6. Gronbaek H, Thogersen T, Frystyk J, et al. Low free and total insulinlike growth factor 1 (IGF-1) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. Am J Gastroenterol 2002; 97:673-678. The growth hormone-IGF1 axis was assessed in 10 adult patients with severe IBD. Total and free IGF1, and IGFBP-3 levels were significantly reduced (by 35%, 53%, and 16%, respectively) in patients as compared with healthy controls. Steroid therapy resulted in a normalization of IGFBP-3 levels, whereas total and free IGF1 concentrations were only partially restored.
7. Akobeng AK, Clayton PE, Miller V, et al. Low serum concentrations of insulin-like growth factor-1 in children with active Crohn disease: effect of enteral nutritional support and glutamine supplementation. Scand J Gastroenterol 2002; 37:1422-1427. This randomized controlled trial showed that neither a standard polymeric diet nor glutamine-enriched, isocaloric and isonitrogenous enteral feeding were able to improve IGF1 levels after 4 weeks of therapy, in children with active Crohn's disease.
8. Corkins MR, Gohil AD, Fitzgerald JF. The insulin-like growth factor axis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003; 36:228-234. This was an uncontrolled study showing that medical therapy could improve IGF1, and IGFBP-3 levels in 17 children with IBD.
9. Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002; 51:127-135. This was a pilot, open-label study on the use of rhGH in children with steroid-dependent IBD. Four-month treatment (0.05 mg/kg/day, subcutaneously) resulted in increased linear growth velocity, and improved body composition. Protein and energy metabolism was not modified.
10. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108:417-422
11. Silvennoinen JA, Karttunen TJ, Niemelae SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71-76.
12. Bjarnason I, MacPherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228-233.
13. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study. Gut 1997; 40:313-319.
14. Semeao EJ, Jawad AF, Stouffer NO, et al. Risk factors for low bone mineral density in children and young adults with Crohn's disease. J Pediatr 1999; 135:593-600.
15. Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: There is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247:63-70.
16. Lee SH, Kim HJ, Yang SK, et al. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol 2000; 15:512-518.
17. Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bone disease. Gastroenterology 2000; 119:1203-1208.
18. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51:654-658. About half of Crohn's disease patients show osteopenia. Twenty-two per cent of them had vertebral fractures. About one third of the patients with fractures are younger than 30 years.
19. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16:1895-1902. Both lumbar spine and femoral neck bone mineral density were reduced in 34 patients newly diagnosed of IBD prior to any steroid therapy, suggesting that osteopenia in highly prevalent early in the course of IBD.
20. Bernstein CN, Leslie WD, Taback SP. Bone desnity in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol 2003; 98:1094-1100. Forty-five patients, of a population-based cohort of 70 premenopausal women in whom IBD was diagnosed before 20 years of age, had normal bone mineral density. Only three (4%) patients were osteoporotic.
21. Habtezion A, Silverberg MS, Parkes R, et al. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8:87-92. This cross-sectional study and the cross-sectional study by de Jong et al. [22] in patients with Crohn's disease disclosed a prevalence of osteopenia of around 50%. Both sets of authors also agree that previous steroid use is a weak predictor of osteopenia in these patients.
22. de Jong DJ, Corstens FH, Mannaerts L, et al. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol 2002; 97:2011-2015. This study also disclosed a prevalence of osteopenia around 50%.
23. Vogelsang H, Ferenci P, Resch H, et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7:609-614.
24. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328:1747-1752.
25. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10:777-786.
26. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996; 23:995-1000.
27. Abitbol V, Mary JY, Roux C, et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002; 16:919-927. This describes a negative randomized controlled trial on the efficacy of adding fluoride to the conventional therapy with calcium and vitamin D in IBD patients with osteoporosis.
28. Fernández Bañares F, Cabré E, Esteve Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr 1995; 19:356-364.
29. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108:1056-1067.
30. Messori A, Trallori G, D'Albasio G, et al. Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Scand J Gastroenterol 1996; 31:267-272.
31. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Gastroenterology 1993; 104:1293-1301.
32. Fernández Bañares F, Cabré E, González-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn's disease. Gut 1994; 35:S55-S59.
33. González-Huix F, De León R, Fernández Bañares F, et al. Polymeric enteral diet as primary treatment of active Crohn's disease: a prospective steroid-controlled trial. Gut 1993; 34:778-782.
34. Gassull MA, Fernández-Bañares F, Cabré E, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut 2002; 51:164-168. This randomized controlled trial was performed to ascertain the hypothesis that diets with either low proinflammatory n-6 polyunsaturated fatty acid, or high monounsaturated fatty acid (e.g. oleic acid) content would be particularly useful in active Crohn's disease. Surprisingly, the remission rates were worse with oleate-enriched diet than with the linoleate diet. Although fat content is a major determinant of the therapeutic effect of enteral feeding in Crohn's disease, the initial hypothesis which needs to be reformulated.
35. Sadeghi S, Wallace FA, Calder PC. Dietary lipids modify the cytokine response to bacterial lipopolysccharide in mice. Immunology 1999; 96:404-410.
36. Middleton SJ, Rucker JT, Kirby GA, et al. Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease. Clin Nutr 1995; 14:229-236.
37. Leiper K, Woolner J, Mullan MM, et al. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Gut 2001; 49:790-794.
38. Bamba T, Shimoyama T, Sasaki M, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol 2003; 15:151-157. This was a small trial confirming the idea that low-fat diets are particularly useful for treating Crohn's disease patients. The four-week remission rate was 80% in patients receiving a low-fat (3 g/day) diet, 40% in those treated with a diet with medium amounts of fat (16.5 g/day), and as low as 25% in those on a high-fat (30 g/day) diet.
39. Sakurai T, Maisui T, Yao T, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. JPEN J Parenter Enteral Nutr 2002; 26:98-103. Response rates of about 70% are reported using either a low-fat (1.5% of energy) elemental diet, or a peptidic diet with 25% of energy as fat - mostly MCT - in patients with active Crohn's disease. This further supports the concept that adding MCT to the diet does not preclude the primary therapeutic effect of enteral feeding.
40. Gorard DA. Enteral nutrition in Crohn's disease: fat in the formula. Eur J Gastroenterol Hepatol 2003; 15:115-118. This is a straightforward discussion about the role of fat in the primary therapeutic effect of enteral nutrition in Crohn's disease.
41. Fuller R. Probiotics. The scientific basis. London: Chapman & Hall; 1992.
42. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998; 39:237-238.
43. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999; 116:1246-1249.
44. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000; 6:107-115.
45. Kennedy RJ, Kirk SJ, Gardiner KR. Promotion of a favorable gut flora in inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2000; 24:189-195.
46. Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000; 95:S19-S21.
47. Shanahan F. Probiotics in inflammatory bowel disease. Gut 2001; 48:609.
48. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13:1103-1108.
49. Sandborn WJ, Waters GS, Pemberton JH. Ileal pouch-anal anastomosis and the problem of pouchitis. Curr Opin Gastroen 1997; 13:34-40.
50. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
51. Ulisse S, Gionchetti P, D'Alo S, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001; 96:2691-2699.
52. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy, a double-blind, placebo-controlled trial. Gastroenterology 2003; 124:1202-1209. Randomized controlled trial on the efficacy of VSL#3 (an eight bacteria strain probiotic cocktail) in the prophylaxis of new onset pouchitis in patients with ileal pouch-anal anastomosis Only two of the 20 patients on VLS#3 developed acute pouchitis, whereas this occurred in eight of 20 patients treated with placebo
53. Katz JA. Prevention is the best defense: Probiotic prophylaxis of pouchitis. Gastroenterology 2003; 124:1535-1538. This is an interesting editorial comment on the mechanisms, importance and future perspectives of probiotic therapy in pouchitis.
54. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51:405-409. This was a negative randomized controlled trial on the effect of Lactobacillus rhamnosus, strain GG in preventing the postoperative recurrence in Crohn's disease, which illustrates the idea that the effects of a certain probiotic mixture should not be extrapolated to other preparations.
55. Bengmark S. Pre-, pro- and synbiotics. Curr Opin Clin Nutr Metabol Care 2001; 4:571-579.
56. Welters CFM, Heineman E, Thunnissen FBJM, et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002; 45:621-627. As compared with placebo, 3 weeks receiving 24 g/day of inulin increased butyrate levels, decreased pH, reduced the numbers of Bacteroides fragilis, and lowered the concentration of secondary bile acids in faeces of patients with ileal pouch-anal anastomosis. This was accompanied by a decrease in inflammation in the reservoir.
57. Kanauchi O, Suga T, Tochihara M, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 2002; 37 (Suppl 14):67-72. The authors describe promising preliminary data of a randomized controlled trial on the effect of a prebiotic foodstuff derived from germinated barley in treatment of mild or moderate active ulcerative colitis.
58. Klein S, Meyers S, O'Sullivan P, et al. The metabolic impact of active ulcerative colitis. Energy expenditure and nitrogen balance. J Clin Gastroenterol 1988; 10:34-40.
59. Kushner RF, Schoeller DA. Resting and total energy expenditure in patients with inflammatory bowel disease. Am J Clin Nutr 1991; 53:161-165.
60. Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41:203-208.
61. Stokes MA, Hill GL. Total energy expenditure in patients with Crohn's Disease: measurement by the combined body scan technique. JPEN J Parenter Enteral Nutr 1993; 17:3-7.
62. Chan ATH, Fleming R, O'Fallon WM, Huitzenga KA. Estimated versus measured basal energy requirements in patients with Crohn's disease. Gastroenterology 1986; 91:75-80.
63. Rigaud D, Cerf M, Alberto LA, et al. Increased resting energy expenditure in acute attacks of Crohn's disease [in French]. Gastroenterol Clin Biol 1993; 17:932-937.
64. Al-Jaouni R, Hébuterne X, Rouget I, Rampal P. Energy metabolism and substrate oxidation in patients with Crohn's disease. Nutrition 2000; 16:173-178.
65. Al-Jaouni R, Schneider SM, Piche T, et al. Effect of steroids on energy expenditure and substrate oxidation in women with Crohn's disease. Am J Gastroenterol 2002; 97:2843-2849. Resting energy expenditure and substrate oxidation were assessed in 29 female patients with Crohn's disease receiving prednisone, budesonide or no steroid therapy. Lipid oxidation was higher in patients with prednisone than in controls and patients with budesonide or no steroid therapy, both during fasting and postprandially. In contrast, protein oxidation was higher in patients on prednisone than in the other groups.
66. Jensen MB, Houborg KB, Vestergaard P, et al. Improved physical performance and increased lean tissue and fat mass in patients with ulcerative colitis four to six years after ileoanal anastomosis with a J-pouch. Dis Colon Rectum 2002; 45:1601-1607. This is an uncontrolled follow-up of 20 ulcerative colitis patients undergoing total proctocolectomy and ileal pouch-anal anastomosis. After 4-6 years of follow-up, they increased their muscular strength, work capacity, total tissue mass (both fat and lean body mass), and bone mineral density.
67. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344:859-861.
68. Fernández Bañares F, Abad Lacruz A, Xiol X, et al. Vitamin status in patients with inflammatory bowel disease. Am J Gastroenterol 1989; 84:744-746.
69. Fernández Bañares F, Mingorance MD, Esteve M, et al. Serum zinc, copper, and selenium levels in inflammatory bowel disease: Effect of total enteral nutrition on trace element status. Am J Gastroenterol 1990; 85:1584-1589.
70. Hoffenberg EJ, Deutsch J, Smith S, Sokol RJ. Circulating antioxidant concentrations in children with inflammatory bowel disease. Am J Ciin Nutr 1997; 65:1482-1488.
71. Miralles-Barrachina O, Savoye G, Belmonte-Zalar L, et al. Low levels of glutathione in endoscopic biopsies of patients with Crohn's colitis: The role of malnutrition. Clin Nutr 1999; 18:313-317.
72. Reimund JM, Hirth C, Koehl C, et al. Antioxidant and immune status in active Crohn's disease. A possible relationship. Clin Nutr 2000; 19:43-48.
73. 2- isoprostane, significantly decreased at 4 weeks as compared with baseline.
74. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277:1775-1781.
75. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-236.
76. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762.
77. Chowers Y, Sela BA, Holland R, et al. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol 2000; 95:3498-3502.
78. Romagnuolo J, Fedorak RN, Dias VC, et al. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001; 96:2143-2149.
79. 6 was normal, although the difference did not reach statistical significance (P = 0.18) probably due to the small size of the sample.